Previous
Previous

Simcha Therapeutics announces first patient dosed in Ph1/2 study evaluating ST-067 in combination with KEYTRUDA® (Pembrolizumab)

Next
Next

FDA accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia